欢迎访问保健网!
China's first Chikungunya virus detection product for market release has been approved by top regulatory authorities, according to the drug administration authorities in Guangdong province.
The Chikungunya virus nucleic acid detection kit, developed by DaAn Gene Co, based in Guangzhou, the provincial capital of Guangdong, received approval from the National Medical Products Administration on Thursday for distribution in the market.
The detection kit is used for the in vitro qualitative detection of Chikungunya virus nucleic acid in serum samples from suspected Chikungunya fever cases and others requiring diagnosis or differential diagnosis of Chikungunya infection.
Drug administration authorities in Guangdong will coordinate with the company to fully organize production preparations and strengthen post-market regulation of the product.
The company said production and clinical use would begin within a week of receiving the certificate, with the maximum daily production capacity adjustable to meet demand, potentially reaching 10 million tests per day within a month to ensure the needs of epidemic control.
附件:
11月13日下午,最高人民检察院党组...
十一期间,记者在南京、上海等多家城市的桓...
2025年11月11—13日,由国家...
11月12日,陕西省卫生健康委规信处...
11月11日,国家药监局局长李利在京...
11月7日上午,湖北省检察机关年轻干...
本站部分信息由相应民事主体自行提供,该信息内容的真实性、准确性和合法性应由该民事主体负责。保健网 对此不承担任何保证责任。
本网部分转载文章、图片等无法联系到权利人,请相关权利人与本网站联系。
保健网 baojianw.org.cn 版权所有。
第一办公区:北京市西城区砖塔胡同56号西配楼;第二办公区:北京市东城区建国门内大街26号新闻大厦5层